“Real world” eligibility for aducanumab: A Podcast with Tim Anderson and Marco Canevelli

We talk with Tim Anderson and Marco Canevelli, the authors of two recent articles published about the real world eligibility of aducanumab.

October 21, 2021 Alex Smith Dementia , Medications Summary Transcript Summary The FDA label for the amyloid antibody aducanumab (Aduhelm) started off exceedingly broad, basically including anyone with Alzheimer’s disease, but was subsequently narrowed to to patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). Should, though, the label be even more restrictive to mirror the populations studied in the two still unpublished trials of the drug, EMERGE and ENGAGE? Or should CMS consider restricting coverage for aducanumab to populations meeting trial e

saved by

• Louis Bannon

related reading

• It’s just a first step, but this new Alzheimer’s drug could be a huge breakthrough | Jonathan Schott | The Guardiantheguardian.com
• Nintil - The failure of monoclonal antibody therapy for Alzheimer's Disease, implications for the Amyloid Cascade Hypothesisnintil.com
• Guidance for Industryfda.gov
• The amyloid hypothesis in Alzheimer disease: new insights from new therapeuticsnature.com
• Inclusion and exclusion criteria - Wikipediaen.wikipedia.org
• Access granted: CMS greenlights more than 150 participants for chronic care experimentstatnews.com
• History of Women’s Participation in Clinical Researchorwh.od.nih.gov
• Physicians Answer More Clinical Questions and Change Clinical Decisions More Often With Synthesized Evidence: A Randomized Trial in Primary Care - PMCncbi.nlm.nih.gov
• Data Gaps that Bottleneck Aging Biomarker Discovery — Norn Groupnorn.group
• Complementary Medicine | UW Department of Bioethics & Humanitiesdepts.washington.edu
• The 23andMe Deal - Cremieux Recueilcremieux.xyz
• Biomarkers for Alzheimer’s Disease in the Current State: A Narrative Review - PMCncbi.nlm.nih.gov